{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:46:43Z","timestamp":1761821203978,"version":"build-2065373602"},"reference-count":99,"publisher":"Elsevier BV","issue":"13-14","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.drudis.2006.05.004","type":"journal-article","created":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T09:32:12Z","timestamp":1150882332000},"page":"623-631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Creating more effective antidepressants: clues from the clinic"],"prefix":"10.1016","volume":"11","author":[{"given":"Kurt","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2006.05.004_bib1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1359-6446(05)03398-2","article-title":"Strategies for producing faster acting antidepressants","volume":"10","author":"Adell","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2006.05.004_bib2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2006.05.004_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib4","first-page":"203","article-title":"Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement","volume":"26","author":"Kerr","year":"2000","journal-title":"Jt. Comm. J. Qual. Improv."},{"issue":"Suppl. 16","key":"10.1016\/j.drudis.2006.05.004_bib5","first-page":"10","article-title":"The definition and meaning of treatment-resistant depression","volume":"62","author":"Sackeim","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 13","key":"10.1016\/j.drudis.2006.05.004_bib6","first-page":"23","article-title":"When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0165-0327(82)90002-7","article-title":"Major tranquillisers used as antidepressants. A review","volume":"4","author":"Robertson","year":"1982","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.drudis.2006.05.004_bib8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.55.3.250","article-title":"Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol","volume":"55","author":"Tollefson","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/da.20017","article-title":"Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia","volume":"20","author":"Kasper","year":"2004","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.drudis.2006.05.004_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004714-199802000-00018","article-title":"Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression","volume":"18","author":"O\u2019Connor","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4088\/JCP.v60n0410","article-title":"Risperidone augmentation of selective serotonin reuptake inhibitors in major depression","volume":"60","author":"Ostroff","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.4088\/JCP.v63n0812","article-title":"An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy","volume":"63","author":"Hirose","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.4088\/JCP.v64n1111","article-title":"Long-term antidepressant efficacy and safety of olanzapine\/fluoxetine combination: a 76-week open-label study","volume":"64","author":"Corya","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4088\/JCP.v66n0407","article-title":"Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients","volume":"66","author":"Sharpley","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4088\/JCP.v66n1012","article-title":"Olanzapine\/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance","volume":"66","author":"Shelton","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/da.10137","article-title":"Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors","volume":"19","author":"Adson","year":"2004","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.drudis.2006.05.004_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4088\/JCP.v65n0212","article-title":"Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder","volume":"65","author":"Papakostas","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib19","first-page":"S99","article-title":"Adjunctive ziprasidone in treatment-resistant depression: randomized, double-blind, 8-week pilot study","volume":"29","author":"Dunner","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2006.05.004_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2004.11.007","article-title":"Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors","volume":"86","author":"Adson","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.drudis.2006.05.004_bib21","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.4088\/JCP.v66n1017","article-title":"Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder","volume":"66","author":"Papakostas","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib22","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.4088\/JCP.v66n1002","article-title":"Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder","volume":"66","author":"Simon","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-200501000-00002","article-title":"Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients","volume":"20","author":"Worthington","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10401230490521954","article-title":"Aripiprazole augmentation in treatment-resistant depression","volume":"16","author":"Barbee","year":"2004","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4088\/JCP.v65n0714","article-title":"The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder","volume":"65","author":"Barbee","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1056\/NEJMcp031002","article-title":"Clinical practice. Obsessive-compulsive disorder","volume":"350","author":"Jenike","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2006.05.004_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/cap.1999.9.115","article-title":"Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder","volume":"9","author":"Fitzgerald","year":"1999","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004850-200015050-00007","article-title":"Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study","volume":"15","author":"Pfanner","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"6","author":"Hollander","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"15","author":"Erzegovesi","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0924-9338(02)00673-9","article-title":"Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment","volume":"17","author":"Crocq","year":"2002","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/070674370104600408","article-title":"Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study","volume":"46","author":"Francobandiera","year":"2001","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib34","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v61n0709","article-title":"Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"61","author":"Koran","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopsych.2003.11.010","article-title":"A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder","volume":"55","author":"Shapira","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4088\/JCP.v65n0418","article-title":"Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial","volume":"65","author":"Bystritsky","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004850-200205000-00004","article-title":"Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study","volume":"17","author":"Atmaca","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib38","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4088\/JCP.v63n0807","article-title":"Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study","volume":"63","author":"Denys","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4088\/JCP.v66n0110","article-title":"Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study","volume":"66","author":"Bogan","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.jcp.0000088900.24613.f1","article-title":"Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder","volume":"23","author":"Sevincok","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib41","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors","volume":"65","author":"Denys","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-244X-5-5","article-title":"Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study","volume":"5","author":"Carey","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib43","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.283.14.1837","article-title":"Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial","volume":"283","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2006.05.004_bib44","first-page":"1","article-title":"Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms","volume":"18","author":"Hamner","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib45","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.biopsych.2004.11.039","article-title":"Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder","volume":"57","author":"Bartzokis","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib46","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1176\/appi.ajp.159.10.1777","article-title":"Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study","volume":"159","author":"Stein","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopsych.2005.07.005","article-title":"Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study","volume":"59","author":"Pollack","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.jcp.0000195108.01898.17","article-title":"Olanzapine augmentation in treatment-resistant panic disorder","volume":"26","author":"Sepede","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1139\/jpn.0312","article-title":"Interactions between the cytochrome P450 system and the second-generation antipsychotics","volume":"28","author":"Prior","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.drudis.2006.05.004_bib50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1345\/aph.1C297","article-title":"Aripiprazole: a new atypical antipsychotic drug","volume":"37","author":"Bowles","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.drudis.2006.05.004_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004714-200208000-00014","article-title":"Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction","volume":"22","author":"Spina","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib52","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1208\/ps040209","article-title":"Influence of fluoxetine on olanzapine pharmacokinetics","volume":"4","author":"Gossen","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.drudis.2006.05.004_bib53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00004714-200204000-00011","article-title":"Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine","volume":"22","author":"Potkin","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib54","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archpsyc.1978.01770330075006","article-title":"\u2018Akinetic depression\u2019 in schizophrenia","volume":"35","author":"Van Putten","year":"1978","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-1781(97)03076-X","article-title":"Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes","volume":"71","author":"Krakowski","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.drudis.2006.05.004_bib56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/19.3.609","article-title":"Subjective response to neuroleptics in schizophrenia","volume":"19","author":"Awad","year":"1993","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.drudis.2006.05.004_bib57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.55.3.250","article-title":"Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol","volume":"55","author":"Tollefson","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004850-200015060-00005","article-title":"Effects of risperidone on affective symptoms in patients with schizophrenia","volume":"15","author":"Peuskens","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib59","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0269881103017002010","article-title":"Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia","volume":"17","author":"Emsley","year":"2003","journal-title":"J. Psychopharmacol."},{"issue":"Suppl. 4","key":"10.1016\/j.drudis.2006.05.004_bib60","first-page":"S9","article-title":"Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders","volume":"17","author":"Montgomery","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib61","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hup.512","article-title":"Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial","volume":"18","author":"Metin","year":"2003","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib62","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.160.2.303","article-title":"Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study","volume":"160","author":"de Haan","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib63","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/026988110201600302","article-title":"Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine","volume":"16","author":"Schmitt","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib64","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/026988110001400405","article-title":"D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study","volume":"14","author":"Meisenzahl","year":"2000","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0924-977X(00)00133-4","article-title":"D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study","volume":"11","author":"Gefvert","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib66","first-page":"1028","article-title":"D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study","volume":"46","author":"la Fougere","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.drudis.2006.05.004_bib67","doi-asserted-by":"crossref","first-page":"992","DOI":"10.4088\/JCP.v63n1106","article-title":"Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade","volume":"63","author":"Tauscher-Wisniewski","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib68","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib69","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib70","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib71","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/00023210-200115090-00001","article-title":"Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies","volume":"15","author":"Tauscher","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2006.05.004_bib72","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0960-894X(02)00996-4","article-title":"SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition","volume":"13","author":"van Hes","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2006.05.004_bib73","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1021\/jm050148z","article-title":"Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition","volume":"48","author":"Smid","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2006.05.004_bib74","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2006.05.004_bib75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2006.05.004_bib76","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2006.05.004_bib77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drudis.2006.05.004_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2006.05.004_bib79","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1124\/jpet.105.089326","article-title":"Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine","volume":"315","author":"Rasmussen","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2006.05.004_bib80","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0361-9230(86)90181-4","article-title":"Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain","volume":"16","author":"Altar","year":"1986","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.drudis.2006.05.004_bib81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0893-133X(88)90001-2","article-title":"Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity","volume":"1","author":"Rasmussen","year":"1988","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2006.05.004_bib82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2006.05.004_bib83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4088\/JCP.v60n0110","article-title":"Mirtazapine augmentation in the treatment of refractory depression","volume":"60","author":"Carpenter","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0447.2001.00148.x","article-title":"Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone","volume":"103","author":"Ferreri","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.drudis.2006.05.004_bib85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/da.10115","article-title":"The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder","volume":"18","author":"Taylor","year":"2003","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.drudis.2006.05.004_bib86","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.npp.1300762","article-title":"The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine","volume":"30","author":"Marek","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2006.05.004_bib87","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib88","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","article-title":"Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study","volume":"355","author":"Newman-Tancredi","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib89","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjp.0702994","article-title":"Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine","volume":"129","author":"Okamura","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib90","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0893-133X(00)00119-6","article-title":"Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex","volume":"23","author":"Zhang","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2006.05.004_bib91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/026988110001400202","article-title":"Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents","volume":"14","author":"Millan","year":"2000","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neulet.2004.03.079","article-title":"Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex","volume":"364","author":"Yoshino","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.drudis.2006.05.004_bib93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1017\/S1461145704004468","article-title":"Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus","volume":"7","author":"Ordway","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2006.05.004_bib94","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2004.02.012","article-title":"Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity","volume":"55","author":"Seager","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2006.05.004_bib95","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00213-005-2198-2","article-title":"Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder","volume":"181","author":"Seager","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drudis.2006.05.004_bib96","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/jpet.102.033282","article-title":"Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons","volume":"302","author":"Szabo","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2006.05.004_bib97","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1523\/JNEUROSCI.20-24-09104.2000","article-title":"Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus","volume":"20","author":"Malberg","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2006.05.004_bib98","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jnr.10281","article-title":"Atypical neuroleptics stimulate neurogenesis in adult rat brain","volume":"69","author":"Wakade","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.drudis.2006.05.004_bib99","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.biopsych.2004.07.008","article-title":"Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat","volume":"56","author":"Kodama","year":"2004","journal-title":"Biol. Psychiatry"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964460600170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964460600170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:57:01Z","timestamp":1761220621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964460600170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":99,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S135964460600170X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2006.05.004","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Creating more effective antidepressants: clues from the clinic","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2006.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}